Medmira Inc (TSE:MIR)

:MIR

MIR

Medmira

RESEARCH TOOLSreports

Want to see TSE:MIR full AI Analyst Report?

Medmira (MIR) Price & Analysis

39 Followers

MIR Stock Chart & Stats

C$0.07

C$0.01(8.70%)

At close: Jan 08 4:00 PM EST

C$0.07

C$0.01(8.70%)

Day’s Range― - ―

52-Week RangeC$0.06 - C$0.11

Previous CloseN/A

Volume74.70K

Average Volume (3M)94.91K

Market Cap

C$42.10M

Enterprise ValueC$59.39M

Total Cash (Recent Filing)C$96.20K

Total Debt (Recent Filing)C$17.39M

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Jul 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding701,730,600

10 Day Avg. Volume79,718

30 Day Avg. Volume94,909

Financial Highlights & Ratios

PEG Ratio-0.35

Price to Book (P/B)-2.47

Price to Sales (P/S)232.06

P/FCF Ratio-17.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary PlatformMedMira’s proprietary Rapid Vertical Flow Technology provides a durable technical moat for point-of-care diagnostics. Platform ownership can shorten development timelines, enable differentiated assays, support licensing/OEM deals, and lower marginal product costs over time, strengthening long-term competitiveness.

Infectious-disease POC Product SetThe company’s focus on HIV and HCV rapid tests targets persistent public-health markets with recurring screening needs. Established test categories face steady demand from clinics, labs and government programs, reducing product-market uncertainty and enabling predictable addressable demand over multiple years.

Consumables & Distribution-driven Revenue ModelMedMira sells test kits plus consumables through distributors and direct channels, creating a recurring revenue opportunity as customers reorder. Consumables-driven demand and distributor relationships can scale geographic reach without heavy fixed selling cost, supporting steadier long-term revenue if volume recovers.

Bears Say

Very Small, Declining RevenueRevenue that has fallen to roughly $0.19M TTM and declined ~19% year-over-year prevents the company from achieving scale needed to absorb fixed costs or fund commercialization. Prolonged revenue shrinkage increases reliance on external funding and limits ability to execute growth or R&D plans.

Negative Equity And Rising DebtAccumulated losses producing roughly -$24M equity alongside rising debt (~$17.4M) versus low assets (~$3.6M) create heightened leverage and solvency risk. This constrains financial flexibility, raises refinancing/default risk, and likely forces dilutive financings or restrictive covenants that impair strategic options.

Persistent Cash BurnConsistent negative operating and free cash flow (~-$2.0M TTM, with free cash flow down ~19%) signals ongoing funding needs. Persistent cash burn pressures runway, limits investment in sales/scale, and increases the probability of equity dilution or creditor-imposed limitations that can materially alter long-term strategy.

Medmira News

MedMira Expands McKesson Partnership as Quarterly Revenue Falls and Loss Widens

Medmira ( ($TSE:MIR) ) just unveiled an update. MedMira reported second-quarter fiscal 2026 results marked by weaker revenue...

26d ago

MedMira Narrows Loss as New Syphilis Test Wins Approval and MiROQ Platform Advances

Medmira ( ($TSE:MIR) ) has shared an update. MedMira reported first-quarter fiscal 2026 results marked by Health Canada...

4M ago

MedMira Inc. Reports FY2025 Financial Results and Strategic Developments

The latest announcement is out from Medmira ( ($TSE:MIR) ). MedMira Inc. reported its FY2025 financial results, highlighting...

5M ago

Health Canada Approves MedMira’s Rapid Syphilis Test Amid Rising Cases

The latest update is out from Medmira ( ($TSE:MIR) ). MedMira Inc. has received approval from Health Canada...

8M ago

MedMira Launches Clinical Trial for HIV/Syphilis Self-Test in Canada

Medmira ( ($TSE:MIR) ) has issued an announcement. MedMira has launched a clinical trial for its Multiplo® TP/HIV...

10M ago

MedMira Reports Q2 FY2025 Results, Advances in STI and HIV Testing

Medmira ( ($TSE:MIR) ) has shared an update. MedMira Inc. reported its second quarter financial results for FY2025,...

10M ago

MedMira Partners with Lovell to Enhance Federal Access to Rapid HIV Testing

Medmira ( ($TSE:MIR) ) has shared an announcement. MedMira Inc. has partnered with Lovell Government Services to expand...

1y ago

MedMira Achieves Regulatory Milestones Amidst Financial Challenges in Q2 FY2025

Medmira ( ($TSE:MIR) ) has shared an update. MedMira Inc. reported its Q2 FY2025 financial results, highlighting significant...

1y ago

MedMira Partners with MediGroup to Expand Reach in US Healthcare Market

The latest announcement is out from Medmira ( ($TSE:MIR) ). MedMira Inc. has announced a partnership with MediGroup,...

1y ago

MedMira Partners with Trimedic to Enhance Rapid Test Distribution in Canada

Medmira ( ($TSE:MIR) ) has provided an update. MedMira Inc. has announced an exclusive distribution agreement with Trimedic...

1y ago

MIR FAQ

What was Medmira Inc’s price range in the past 12 months?

Medmira Inc lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.

What is Medmira Inc’s market cap?

Medmira Inc’s market cap is C$42.10M.

When is Medmira Inc’s upcoming earnings report date?

Medmira Inc’s upcoming earnings report date is Jul 07, 2026 which is in 71 days.

How were Medmira Inc’s earnings last quarter?

Medmira Inc released its earnings results on Apr 02, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.

Is Medmira Inc overvalued?

According to Wall Street analysts Medmira Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medmira Inc pay dividends?

Medmira Inc does not currently pay dividends.

What is Medmira Inc’s EPS estimate?

Medmira Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medmira Inc have?

Medmira Inc has 701,730,600 shares outstanding.

What happened to Medmira Inc’s price movement after its last earnings report?

Medmira Inc reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.077%.

Which hedge fund is a major shareholder of Medmira Inc?

Currently, no hedge funds are holding shares in TSE:MIR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medmira Inc

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.